Search
Cenegermin
go.drugbank.com/drugs/DB13926ApprovedInvestigationalIt received European Union Approval in July 2017 for the treatment of moderate to severe neurotrophic keratitis. Cenegermin received approval from the US FDA a year later in August of 2018. … [L4563] Neurotrophic keratitis is a degenerative disease resulting from a loss of corneal sensation.
Avatrombopag
go.drugbank.com/drugs/DB11995ApprovedInvestigational[L2931] It is administered orally as the salt form avatrombopag maleate. … This approval was supported by results from the AVA-PED-301 phase 3 study, which demonstrated durable platelet responses and favorable safety in children with persistent or chronic immune thrombocytopenia
Carbon monoxide
go.drugbank.com/drugs/DB11588ApprovedInvestigationalThis use of CO has been generally recognized as safe (GRAS) in several packaging applications for fresh meat products. … The DLCO measures the ability of the lungs to transfer gas from inhaled air to the red blood cells in pulmonary capillaries. The DLCO test is both convenient and simple for the patient to undergo.
Tazobactam
go.drugbank.com/drugs/DB01606ApprovedInvestigationalPiperacillin-tazobactam was initially approved by the FDA in 1994, and ceftolozane-tazobactam was approved by the FDA in 2014[FDA label], providing wider antibacterial coverage for gram-negative infections … In June 2019, ceftolozane-tazobactam was approved by the FDA for treating hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia, which are significant causes of morbidity
Mixtures: Zerbaxa 1.5g powder for solution for injection, ZERBAXA POWDER FOR SOLUTION FOR INJECTION 1G/0.5GCategories: Antibacterials for Systemic Use, Antiinfectives for Systemic UseBecaplermin
go.drugbank.com/drugs/DB00102ApprovedInvestigationalBecaplermin is produced by recombinant DNA technology by insertion of the gene for the B chain of platelet derived growth factor (PDGF) into the yeast, Saccharomyces cerevisiae. … Becaplermin has a molecular weight of approximately 25 KD and is a homodimer composed of two identical polypeptide chains that are bound together by disulfide bonds.
Categories: Preparations for Treatment of Wounds and UlcersCabozantinib
go.drugbank.com/drugs/DB08875ApprovedInvestigational[L15123] In 2016, a capsule formulation (Cabometyx) was approved for the treatment of advanced renal cell carcinoma, and this same formulation gained additional approval in both the US and Canada in 2019 … It was initially approved in the US under the brand name Cometriq, which is indicated for the treatment of metastatic medullary thyroid cancer.
Voxelotor
go.drugbank.com/drugs/DB14975Approved[T734] Voxelotor was granted accelerated FDA approval on November 25 2019, as it is likely to be a promising treatment for the 100,000 individuals in the U.S. suffering from the disease, in addition … [L10403] It was developed by Global Blood Therapeutics, Inc.
Carisoprodol
go.drugbank.com/drugs/DB00395Approvedfor abuse in addition to a low risk of dependence [L5074]. … This drug is available by itself in an oral tablet or combined with aspirin, or in a fixed-dose combination with both aspirin and codeine [FDA label, F4060, F4069].
Niclosamide
go.drugbank.com/drugs/DB06803ApprovedInvestigationalVet approvedNiclosamide, once marketed in the US under the brand name Niclocide, was voluntarily withdrawn from market by Bayer in 1996.[L11860] … Niclosamide is an antihelminthic used for the treatment of tapeworm infections.
Categories: Compounds used in a research, industrial, or household settingGolodirsen
go.drugbank.com/drugs/DB15593ApprovedInvestigational[L10773] Golodirsen was developed by Sarepta Therapeutics and granted accelerated FDA approval on December 12, 2019 due to the urgent need for this drug in patients suffering from a certain form of … Often, patients succumb to this condition by age 30 or younger due to cardiac and respiratory complications.
Categories: Compounds used in a research, industrial, or household setting